

# Risk factors for pregnancy failure in patients with anti- with conventional therapies: a multicentre, case-control

Rheumatology

50, 1684-1689

DOI: [10.1093/rheumatology/ker139](https://doi.org/10.1093/rheumatology/ker139)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Obstetric antiphospholipid syndrome: conclusions confounded by small sample sizes and uncertain antibody profiles. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 1521-1521.	1.5	0
2	Repeated miscarriages in patients with antiphospholipid syndrome and subjected to in vitro fertilization: the importance of preimplantation genetic diagnosis. <i>Lupus</i> , 2012, 21, 744-746.	1.6	5
3	Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2012, 24, 473-481.	4.3	30
4	Hypertension negatively affects the pregnancy outcome in patients with antiphospholipid syndrome. <i>Lupus</i> , 2012, 21, 810-812.	1.6	5
6	The significance of autoantibodies against $\beta_2$ -glycoprotein I. <i>Blood</i> , 2012, 120, 266-274.	1.4	126
7	Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2012, 12, 313-317.	5.8	94
9	Syndr�me des antiphospholipides: ateliers. <i>Revue De Medecine Interne</i> , 2012, 33, A8-A14.	1.0	0
10	Risk-based secondary prevention of obstetric antiphospholipid syndrome. <i>Lupus</i> , 2012, 21, 741-743.	1.6	8
12	Anti-phospholipid induced murine fetal loss: Novel protective effect of a peptide targeting the $\beta_2$ glycoprotein I phospholipid-binding site. Implications for human fetal loss. <i>Journal of Autoimmunity</i> , 2012, 38, J209-J215.	6.5	58
13	Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2012, 38, J197-J208.	6.5	69
14	Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. <i>Lupus</i> , 2012, 21, 1183-1189.	1.6	48
15	Pregnancy and Antiphospholipid Syndrome. <i>American Journal of Reproductive Immunology</i> , 2013, 69, 585-587.	1.2	7
16	Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2012, 64, 2311-2318.	6.7	308
17	Beyond the "syndrome": Antiphospholipid antibodies as risk factors. <i>Arthritis and Rheumatism</i> , 2012, 64, 342-345.	6.7	25
19	Receptors involved in cell activation by antiphospholipid antibodies. <i>Thrombosis Research</i> , 2013, 132, 408-413.	1.7	32
20	Top 10 Clinical Research Developments in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2013, 15, 367.	4.7	4
21	Analytical Detection Capabilities of Immunoassay-Based Antiphospholipid Antibody Tests: Do They Matter?. <i>Drug Development Research</i> , 2013, 74, 575-581.	2.9	2
22	Anticoagulation in Management of Antiphospholipid Antibody Syndrome in Pregnancy. <i>Clinics in Laboratory Medicine</i> , 2013, 33, 367-376.	1.4	19

#	ARTICLE	IF	CITATIONS
23	Management of Women with Recurrent Pregnancy Losses and Antiphospholipid Antibody Syndrome. American Journal of Reproductive Immunology, 2013, 69, 596-607.	1.2	25
26	Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes. Rheumatology, 2013, 52, 1642-1647.	1.9	29
27	Antiphospholipid Antibodies Affect Human Endometrial Angiogenesis: Protective Effect of a Synthetic Peptide (TIF) Mimicking the Phospholipid Binding Site of Î² <sub>2</sub> glycoprotein I. American Journal of Reproductive Immunology, 2013, 70, 299-308.	1.2	44
28	Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Review of Clinical Immunology, 2014, 10, 1505-1517.	3.0	25
29	Maladies de systÃme. , 2014, , 17-54.		0
30	Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies. Lupus Science and Medicine, 2014, 1, e000034.	2.7	16
32	Treatment of the antiphospholipid syndrome. Autoimmunity Highlights, 2014, 5, 1-7.	3.9	17
34	Management of Recurrent Thrombosis in Antiphospholipid Syndrome. Current Rheumatology Reports, 2014, 16, 405.	4.7	33
35	Pregnancy Morbidity in Antiphospholipid Syndrome: What Is the Impact of Treatment?. Current Rheumatology Reports, 2014, 16, 403.	4.7	38
36	14th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. Autoimmunity Reviews, 2014, 13, 795-813.	5.8	161
37	Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder. Autoimmunity Reviews, 2014, 13, 901-908.	5.8	50
39	Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Research and Therapy, 2014, 16, 209.	3.5	99
40	Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine?. British Journal of Haematology, 2014, 165, 585-599.	2.5	40
41	Current treatment strategies for management of antiphospholipid syndrome. Expert Opinion on Orphan Drugs, 2014, 2, 205-215.	0.8	0
42	Role of antiphospholipid score and anti-Î² <sub>2</sub> -glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clinica Chimica Acta, 2014, 431, 174-178.	1.1	33
43	Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood, 2014, 123, 404-413.	1.4	140
44	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. Thrombosis and Haemostasis, 2014, 112, 727-735.	3.4	102
45	Laboratory Methodology Important in the Diagnosis and Prognosis of Antiphospholipid Syndrome. , 2015, , .		1

#	ARTICLE	IF	CITATIONS
46	Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block. <i>Transfusion and Apheresis Science</i> , 2015, 53, 269-278.	1.0	17
48	State of the art: Reproduction and pregnancy in rheumatic diseases. <i>Autoimmunity Reviews</i> , 2015, 14, 376-386.	5.8	169
49	The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus. <i>Prenatal Diagnosis</i> , 2015, 35, 447-452.	2.3	9
51	Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. <i>Clinica Chimica Acta</i> , 2015, 446, 201-205.	1.1	38
52	Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II. <i>Reumatología Clínica</i> , 2015, 11, 305-315.	0.5	17
53	Clinical Practice Guidelines for the Management of Pregnancy in Women With Autoimmune Rheumatic Diseases of the Mexican College of Rheumatology. Part II. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 305-315.	0.3	3
54	The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2015, 14, 498-502.	5.8	152
55	Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part I. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 295-304.	0.3	12
56	Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?. <i>Autoimmunity Reviews</i> , 2015, 14, 760-762.	5.8	34
58	Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome?. <i>Autoimmunity Reviews</i> , 2015, 14, 23-29.	5.8	62
59	Predictors of Pregnancy Outcome in Antiphospholipid Syndrome: A Review. <i>Journal of Allergy &amp; Therapy</i> , 2016, 7, .	0.1	2
60	Systemic lupus erythematosus: strategies to improve pregnancy outcomes. <i>International Journal of Women's Health</i> , 2016, Volume 8, 265-272.	2.6	24
61	The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome. <i>Antibodies</i> , 2016, 5, 16.	2.5	27
62	Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. <i>PLoS ONE</i> , 2016, 11, e0158757.	2.5	25
64	The role of anti-phospholipid antibodies in autoimmune reproductive failure. <i>Reproduction</i> , 2016, 151, R79-R90.	2.6	21
65	Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. <i>Journal of Reproductive Immunology</i> , 2016, 115, 14-19.	1.9	49
66	Connective Tissue Disease. <i>Rare Diseases of the Immune System</i> , 2016, , .	0.1	2
67	Pregnancy in women with systemic lupus erythematosus (SLE). <i>European Journal of Internal Medicine</i> , 2016, 32, 7-12.	2.2	64

#	ARTICLE	IF	CITATIONS
68	Classic and Global Hemostasis Testing in Pregnancy and during Pregnancy Complications. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 696-716.	2.7	26
69	Pregnancy in patients with autoimmune disease: A reality in 2016. <i>Autoimmunity Reviews</i> , 2016, 15, 975-977.	5.8	47
70	ApoE Receptor 2 Mediation of Trophoblast Dysfunction and Pregnancy Complications Induced by Antiphospholipid Antibodies in Mice. <i>Arthritis and Rheumatology</i> , 2016, 68, 730-739.	5.6	56
71	Human extravillous trophoblasts bind but do not internalize antiphospholipid antibodies. <i>Placenta</i> , 2016, 42, 9-16.	1.5	18
72	Performance Characteristics of Commercial Immunoassays for the Detection of IgG and IgM Antibodies to $\beta$ 2Glycoprotein I and an Initial Assessment of Newly Developed Reference Materials for Assay Calibration. <i>American Journal of Clinical Pathology</i> , 2016, 145, 796-805.	0.7	10
73	Pregnancy and autoimmune connective tissue diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 63-80.	3.3	50
74	Pregnancy and contraception in systemic and cutaneous lupus erythematosus. <i>Annales De Dermatologie Et De Venereologie</i> , 2016, 143, 590-600.	1.0	12
75	Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. <i>Lupus</i> , 2016, 25, 911-916.	1.6	43
76	Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. <i>Lupus Science and Medicine</i> , 2016, 3, e000131.	2.7	118
77	Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 28-39.	6.5	16
78	Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome—A Retrospective Analysis and a Review of Additional Treatment in Pregnancy. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 54-67.	6.5	14
79	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 476-485.	0.9	590
80	Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps. <i>Pharmacological Research</i> , 2017, 123, 146-156.	7.1	77
81	Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. <i>Lupus</i> , 2017, 26, 983-988.	1.6	48
82	Obstetric Manifestations of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 107-120.	0.1	0
84	Antiphospholipid antibodies and the risk of pregnancy complications. <i>Thrombosis Research</i> , 2017, 151, S34-S37.	1.7	12
85	Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 730-734.	5.8	63
87	Controversies Concerning the Antiphospholipid Syndrome in Obstetrics. <i>Reumatologia Clínica</i> (English Edition), 2017, 13, 30-36.	0.3	0

#	ARTICLE	IF	CITATIONS
88	Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. Best Practice and Research in Clinical Rheumatology, 2017, 31, 397-414.	3.3	74
89	Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers. Current Rheumatology Reports, 2017, 19, 43.	4.7	11
90	Diagnosis and management of the antiphospholipid syndrome. Blood Reviews, 2017, 31, 406-417.	5.7	120
91	Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: A multicenter study. Journal of Reproductive Immunology, 2017, 122, 21-27.	1.9	36
92	Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine, 2017, 55, 890-898.	2.3	49
93	Controversias del sÃndrome de anticuerpos antifosfolipÃdicos en obstetricia. ReumatologÃa ClÃnica, 2017, 13, 30-36.	0.5	3
94	Stillbirth: the impact of antiphospholipid syndrome?. Lupus, 2017, 26, 237-239.	1.6	8
95	Management of Systemic Lupus Erythematosus During Pregnancy. Annual Review of Medicine, 2017, 68, 271-285.	12.2	19
96	Antiphospholipid Antibodies and Reproduction. , 0, , 113-123.		0
97	6 Antiphospholipidsyndrom. , 2017, , 93-110.		0
98	An ever-challenging relationship: lupus and pregnancy. Reumatologia, 2017, 55, 37-45.	1.1	12
99	Pregnancy and Rheumatic Diseases. , 2017, , 572-586.		3
100	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thrombosis and Haemostasis, 2018, 47, 639-646.	3.4	62
101	Are Anti-Î²2 Glycoprotein 1 Antibodies Associated with Placenta-Mediated Pregnancy Complications? A Nested Caseâ€“Control Study. American Journal of Perinatology, 2018, 35, 1093-1099.	1.4	6
102	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. Journal of Autoimmunity, 2018, 90, 1-27.	6.5	60
103	Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study. Scandinavian Journal of Rheumatology, 2018, 47, 501-504.	1.1	5
104	Antiphospholipid antibody profile-based outcome of purely vascular and purely obstetric antiphospholipid syndrome. Journal of Thrombosis and Thrombolysis, 2018, 46, 166-173.	2.1	5
105	Update on Antiphospholipid Syndrome: Ten Topics in 2017. Current Rheumatology Reports, 2018, 20, 15.	4.7	22

#	ARTICLE	IF	CITATIONS
106	Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients. <i>Clinical Rheumatology</i> , 2018, 37, 1295-1303.	2.2	35
107	Clinical feature and anti-phospholipid antibody profiles of pregnancy failure in young women with antiphospholipid antibody syndrome treated with conventional therapy. <i>Modern Rheumatology</i> , 2018, 28, 670-675.	1.8	6
109	Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women. <i>Arthritis Research and Therapy</i> , 2018, 20, 249.	3.5	12
110	Obstetric antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2018, 5, e000197.	2.7	42
111	What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?. <i>Immunologic Research</i> , 2018, 66, 577-583.	2.9	6
113	Clinical value of anti-domain I <sup>1</sup> 2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study. <i>Clinica Chimica Acta</i> , 2018, 485, 74-78.	1.1	13
114	Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies. <i>Frontiers in Immunology</i> , 2018, 9, 864.	4.8	34
115	Obstetric Anti-phospholipid Syndrome: State of the Art. <i>Current Rheumatology Reports</i> , 2018, 20, 59.	4.7	12
116	Antiphospholipid syndrome: An update on risk factors for pregnancy outcome. <i>Autoimmunity Reviews</i> , 2018, 17, 956-966.	5.8	54
117	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. <i>Frontiers in Immunology</i> , 2019, 10, 1948.	4.8	33
118	Antiphospholipid syndrome: a clinical review. <i>Medical Journal of Australia</i> , 2019, 211, 184-188.	1.7	16
119	Complementemia in pregnancies with antiphospholipid syndrome. <i>Lupus</i> , 2019, 28, 1503-1509.	1.6	20
120	Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome. <i>American Journal of Reproductive Immunology</i> , 2019, 82, e13185.	1.2	14
122	Therapeutic apheresis during pregnancy: A single center experience. <i>Transfusion and Apheresis Science</i> , 2019, 58, 652-658.	1.0	23
123	The association between antiphospholipid antibodies and late fetal loss: A systematic review and meta-analysis. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 1523-1533.	2.8	23
124	IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. <i>Thrombosis Research</i> , 2019, 177, 157-160.	1.7	30
126	What's new in obstetric antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 421-425.	2.5	8
127	Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2891.	4.8	8

#	ARTICLE	IF	CITATIONS
128	High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. <i>Blood Advances</i> , 2019, 3, 769-776.	5.2	17
129	Management of pregnant women with antiphospholipid antibodies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 347-358.	3.0	18
130	Antiphospholipid antibodies are associated with positive screening for common mental disorders in women with previous pregnancy loss. The NOHA-PSY observational study. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 51-63.	2.6	11
131	Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 036-043.	3.4	11
132	Antiphospholipid syndrome: Diagnosis and management in the obstetric patient. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 64, 31-40.	2.8	18
133	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101463.	3.3	92
134	Detection of anti-β <sub>2</sub> -glycoprotein I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: A multicenter multiplatform study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 463-478.	3.8	20
135	The Complement System in the Pathophysiology of Pregnancy and in Systemic Autoimmune Rheumatic Diseases During Pregnancy. <i>Frontiers in Immunology</i> , 2020, 11, 2084.	4.8	30
136	16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1601-1615.	1.6	27
137	Prevention of Pregnancy Complications in Antiphospholipid Syndrome. <i>Hamostaseologie</i> , 2020, 40, 174-183.	1.9	6
140	The β <sub>2</sub> -glycoprotein I/HLA-DR Complex As a Major Autoantibody Target in Obstetric Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2020, 72, 1882-1891.	5.6	16
141	Risk factors for pregnancy failure in patients with antiphospholipid antibody positivity and prior pregnancy losses: A retrospective study. <i>Journal of Reproductive Immunology</i> , 2020, 141, 103171.	1.9	1
142	The antiphospholipid syndrome “often overlooked cause of vascular occlusions?”. <i>Journal of Internal Medicine</i> , 2020, 287, 349-372.	6.0	27
143	Antiphospholipid antibodies can specifically target placental mitochondria and induce ROS production. <i>Journal of Autoimmunity</i> , 2020, 111, 102437.	6.5	19
144	Anti-phospholipid antibodies and reproductive failures. <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13258.	1.2	13
145	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts™ Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	5.8	38
146	The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 28-35.	3.4	18
147	Clinical features of new-onset systemic lupus erythematosus during pregnancy in Central China: a retrospective study of 68 pregnancies. <i>Clinical Rheumatology</i> , 2021, 40, 2121-2131.	2.2	9



#	ARTICLE	IF	CITATIONS
148	The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics. Archives of Gynecology and Obstetrics, 2021, 303, 455-461.	1.7	10
149	RESULTADOS OBSTÁTRICOS EN GESTANTES DIAGNOSTICADAS DE SÍNDROME ANTIFOSFOLÍPIDO. Revista Médica Clínica Las Condes, 2021, 32, 128-135.	0.2	0
150	Spinal Anesthesia for Cesarean Section in a Coagulated Patient with Antiphospholipid Syndrome. Bali Journal of Anesthesiology, 2021, 5, 135.	0.1	0
151	Predictive value of quad serum markers for adverse pregnancy outcome in antiphospholipid antibody syndrome. Lupus, 2021, 30, 981-990.	1.6	0
152	Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines. Expert Review of Hematology, 2021, 14, 457-466.	2.2	4
153	Risk factors for pregnancy morbidity in women with antiphospholipid syndrome. Journal of Reproductive Immunology, 2021, 145, 103315.	1.9	3
154	The impact of various entities of antiphospholipid antibodies positivity on adverse pregnancy outcome. An epidemiological perspective. Journal of Reproductive Immunology, 2021, 145, 103304.	1.9	3
155	Obstetric antiphospholipid syndrome. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 495-501.	0.8	0
156	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. Biomedicine, 2021, 9, 671.	3.2	17
157	Obstetric anti-phospholipid syndrome: from pathogenesis to treatment. Immunological Medicine, 2022, 45, 79-93.	2.6	8
158	The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. Thrombosis Research, 2021, 206, 104-110.	1.7	15
160	Prevention and Treatment of Obstetric Antiphospholipid Syndrome. , 2017, , 235-246.		1
161	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. Rheumatology, 2021, 60, 1114-1124.	1.9	41
162	Diagnosis and therapy of antiphospholipid syndrome. Polish Archives of Internal Medicine, 2015, 125, 672-677.	0.4	15
163	Schwangerschaft bei entzündlich rheumatischen Erkrankungen. , 2015, , 99-110.		0
169	The Impact of aPL Detection on Pregnancy. Rare Diseases of the Immune System, 2016, , 169-181.	0.1	0
170	Síndrome antifosfolípídico. EMC - Aparato Locomotor, 2019, 52, 1-16.	0.1	0
172	Maternal and neonatal outcomes of pregnancy complicated with Systemic Lupus Erythematosus. Food Science and Technology, 0, , .	1.7	1

#	ARTICLE	IF	CITATIONS
173	Obstetric Antiphospholipid Syndrome. , 0, , .		0
174	Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 354-362.	1.6	5
177	Treatment of Refractory/High-Risk Pregnancies With Antiphospholipid Syndrome: A Systematic Review of the Literature. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	2
178	Anti-Phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an all-comer population. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2070-2074.	3.8	9
179	Preparing for Pregnancy in Women with Systemic Lupus Erythematosus—A Multidisciplinary Approach. <i>Medicina (Lithuania)</i> , 2022, 58, 1371.	2.0	1
181	Alternative pathway activation in pregnancy, a measured amount of complements—a successful pregnancy, too much results in adverse events. <i>Immunological Reviews</i> , 2023, 313, 298-319.	6.0	3
182	Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
183	Rheumatologische Krankheiten und Schwangerschaft: Systemischer Lupus erythematoses, Antiphospholipidsyndrom, rheumatoide Arthritis, Spondyloarthritis, systemische Sklerose, entzündliche Myopathien und Vaskulitis. <i>Springer Reference Medizin</i> , 2022, , 1-20.	0.0	0
184	Antiphospholipid antibodies in chronic thromboembolic pulmonary hypertension. <i>European Journal of Internal Medicine</i> , 2023, 111, 1-4.	2.2	2
185	Management and outcomes of women with antiphospholipid syndrome during pregnancy. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 55, 751-759.	2.1	2
186	Low complement levels are related to poor obstetric outcomes in women with obstetric antiphospholipid syndrome. The EUROAPS Registry Study Group. <i>Placenta</i> , 2023, 136, 29-34.	1.5	4
187	Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach. <i>Current Opinion in Rheumatology</i> , 2023, 35, 149-160.	4.3	5
188	Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study. <i>RMD Open</i> , 2023, 9, e002534.	3.8	6
189	Assessment-based management of placenta-mediated pregnancy complications: Pragmatism until a precision medicine approach evolves. <i>British Journal of Haematology</i> , 2023, 202, 18-30.	2.5	2
190	Maladies de système. , 2022, , 19-61.		0
191	Challenges in Family Planning and Pregnancy for Women with Rheumatic Diseases. , 2023, 2, 28.		0
192	Autoimmunerkrankungen. , 2023, , 319-349.		0
193	Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study. <i>Journal of Autoimmunity</i> , 2024, 144, 103180.	6.5	0